• Acumen presented non-human primate data for its Enhanced Brain Delivery bispecific antibody program targeting Aβ oligomers via transferrin receptor transport.
• Lead candidate ACU401 reached up to 40-fold higher frontal cortex exposure at 24 hours versus ACU234 alone; at least 14-fold for other constructs.
• Study reported no hematological safety signals in cynomolgus monkeys, reducing concern about anemia risk from transferrin receptor targeting.
• Results support advancing an EBD construct toward clinical trials, aiming to lower required dose and enable low-volume delivery devices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150730PRIMZONEFULLFEED9762189) on July 15, 2026, and is solely responsible for the information contained therein.